The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Open accessAbstract
Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient. This heterogeneity in treatment response could result from genetic modifiers that regulate the degree to which tumour cells are dependent on mutant EGFR. Through a pooled RNA interference screen, we show that knockdown of FAS and several components of the NF-κB pathway specifically enhanced cell death induced by the EGFR TKI erlotinib in EGFR-mutant lung cancer cells. Activation of NF-κB through overexpression of c-FLIP or IKK (also known as CFLAR and IKBKB, respectively), or silencing of IκB (also known as NFKBIA), rescued EGFR-mutant lung cancer cells from EGFR TKI treatment. Genetic or pharmacologic inhibition of NF-κB enhanced erlotinib-induced apoptosis in erlotinib-sensitive and erlotinib-resistant EGFR-mutant lung cancer models. Increased expression of the NF-κB inhibitor IκB predicted for improved response and survival in EGFR-mutant lung cancer patients treated with EGFR TKI. These data identify NF-κB as a potential companion drug target, together with EGFR, in EGFR-mutant lung cancers and provide insight into the mechanisms by which tumour cells escape from oncogene dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In erlotinib-sensitive and erlotinib-resistant EGFR-mutant lung cancer models, genetic or pharmacologic inhibition of NF-κB increased erlotinib-induced apoptosis [114].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationScreening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citationPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
Luo, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26322 · Cited by 898
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 514
Cited by
Sorted by citations
Items 201–300 of 400
Cho, J. H., You, Y.-M., Yeom, Y. I., Lee, D. C., Kim, B., Won, M., Cho, B. C., Kang, M., Park, S., Yang, S.-J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0651-5 · Cited by 31
Cardamonin attenuates chronic inflammation and tumorigenesis in colon
Hou, S., Yuan, Q., Yu, N., Liu, B., Huang, G., & Yuan, X. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1673620 · Cited by 31
Cioce, M., & Fazio, V. M. (2021) · Cancers · doi:10.3390/cancers13040700 · Cited by 31
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
Galvani, E., Sun, J., León, L. G., Sciarrillo, R., Narayan, R. S., Sjin, R. T. T., Lee, K., Ohashi, K., Heideman, D. A. M., Alfieri, R. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3956 · Cited by 32
PP2A mediates apoptosis or autophagic cell death in multiple myeloma cell lines
Zhou, H., Luo, W., Zeng, C., Zhang, Y., Wang, L., Yao, W., & Nie, C. (2017) · Oncotarget · doi:10.18632/oncotarget.20415 · Cited by 32
New strategies for targeting drug combinations to overcome mutation-driven drug resistance
Wang, L., Wang, H., Song, D., Xu, M., & Liebmen, M. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.002 · Cited by 30
Shi, P., Zhang, S., Zhu, L., Qian, G., Ren, H., Ramalingam, S. S., Chen, M., & Sun, S. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.02.006 · Cited by 30
Liu, Y., Dai, X., Jiang, S., Qahar, M., Feng, C., Guo, D., Wang, L., Ma, S., & Huang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23148025 · Cited by 30
Xian, H., Feng, W., & Zhang, J. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.016 · Cited by 30
At the crossroads of cancer stem cells and targeted therapy resistance
Wang, A., Qu, L., & Wang, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.039 · Cited by 31
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment
Zaman, A., & Bivona, T. G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.02 · Cited by 29
Self-citationDrug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
Suda, K., & Mitsudomi, T. (2021) · Cells · doi:10.3390/cells10071590 · Cited by 30
Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer.
Shien, K., Yamamoto, H., Soh, J., Miyoshi, S., & Toyooka, S. (2014) · PubMed · doi:10.18926/amo/52785 · Cited by 29
Zhu, X., Gu, J., & Qian, H. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.09.005 · Cited by 29
Santarpía, M., Magrí, I., Sanchez-Ronco, M., Costa, C., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Bertrán-Alamillo, J., Mayo, C., Benlloch, S., Viteri, S., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-163 · Cited by 28
Self-citationRole of Genotyping in Non-Small Cell Lung Cancer Treatment
Bonanno, L., Favaretto, A. G., Rugge, M., Tarón, M., & Rosell, R. (2011) · Drugs · doi:10.2165/11597700-000000000-00000 · Cited by 29
Self-citationJeong, J.-H., Cho, B. C., Shim, H. S., Kim, H. R., Lim, S.-M., Kim, S. I., Chung, K. Y., Islam, S. M. B. U., Song, J. J., Kim, S., et al. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.7.1005 · Cited by 28
Nishino, K., Imamura, F., Morita, S., Mori, M., Komuta, K., Kijima, T., Namba, Y., Kumagai, T., Yamamoto, S., Tachibana, I., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.009 · Cited by 27
Systems biology approaches to develop innovative strategies for lung cancer therapy
Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.28 · Cited by 27
Jin, L., Zhang, B., Hua, S., Ji, M., Huang, X., Huang, R.-Z., & Wang, H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.025 · Cited by 27
Feng, J., Li, S., Zhang, B., Duan, N., Zhou, R., Yan, S.-K., Elango, J., Liu, N., & Wu, W. (2022) · Marine Drugs · doi:10.3390/md20010076 · Cited by 26
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Delaney, C. D., Frank, S., & Huang, R. S. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0007-9 · Cited by 27
Lu, C., Xiong, M., Luo, Y. M., Li, J., Zhang, Y., Dong, Y., Zhu, Y., Niu, T., Wang, Z., & Duan, L.-N. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0875-x · Cited by 26
Hussmann, D., Madsen, A. T., Jakobsen, K. R., Luo, Y., Sørensen, B. S., & Nielsen, A. L. (2017) · Oncotarget · doi:10.18632/oncotarget.16350 · Cited by 26
RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Xu, Z., Hang, J., Hu, J., & Gao, B. (2013) · Europe PMC (PubMed Central) · Cited by 25
Presutti, D., Santini, S., Cardinali, B., Papoff, G., Lalli, C., Samperna, S., Fustaino, V., Giannini, G., & Ruberti, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143333 · Cited by 25
Zhan, Y., Wang, Y., Qi, M., Liang, P., Ma, Y., Li, T., Li, H., Dai, C., An, Z., Qi, Y., et al. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0322-y · Cited by 25
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency
Takeda, H., Takigawa, N., Ohashi, K., Minami, D., Kataoka, I., Ichihara, E., Ochi, N., Tanimoto, M., & Kiura, K. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.12.018 · Cited by 25
Cell death in cancer therapy of lung adenocarcinoma
Zagryazhskaya, A., Gyurászová, K., & Zhivotovsky, B. (2015) · The International Journal of Developmental Biology · doi:10.1387/ijdb.150044bz · Cited by 25
Ke, C., Zhu, K., Sun, Y., Ni, Y., Zhang, Z., & Li, X. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12895 · Cited by 25
Novel molecular targets for the treatment of lung cancer
Rosell, R., Karachaliou, N., & Arrieta, O. G. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000590 · Cited by 24
Self-citationERK inhibition represses gefitinib resistance in non-small cell lung cancer cells
Qi, M., Tian, Y., Wang, L., Li, D., Zhao, T., Yang, Y., Li, Q., Chen, S., Yang, Y., Zhang, Z., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24147 · Cited by 24
Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data
Xia, Z., Ou-yang, W., Hu, T., & Du, K. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.04.001 · Cited by 24
Monet, M., Poët, M., Tauzin, S., Fouqué, A., Cophignon, A., Lagadic‐Gossmann, D., Vacher, P., Legembre, P., & Counillon, L. (2016) · Scientific Reports · doi:10.1038/srep28008 · Cited by 24
Gong, Q., Chen, X., Liu, F., & Cao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1216585 · Cited by 23
CD95 signaling in colorectal cancer
Hoogwater, F. J. H., Steller, E. J. A., Westendorp, B. F., Rinkes, I. H. M. B., & Kranenburg, O. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.007 · Cited by 23
Peters, S., & Meylan, E. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835d720b · Cited by 23
Structure-Driven Developments of 26S Proteasome Inhibitors
Sledz, P., & Baumeister, W. P. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124727 · Cited by 25
Sakuma, Y., Yamazaki, Y., Nakamura, Y., Yoshihara, M., Matsukuma, S., Koizume, S., & Miyagi, Y. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.009 · Cited by 24
Sudo, M., Mori, S., Madan, V., Yang, H. H., Leong, G., & Koeffler, H. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2891 · Cited by 24
Liu, B., Song, S., Setroikromo, R., Chen, S., Hu, W., Chen, D., van der Wekken, A. J., Melgert, B. N., Timens, W., van den Berg, A., et al. (2019) · Cancers · doi:10.3390/cancers11040455 · Cited by 22
Wang, W., Shang, Y., Wang, C., Ni, J., Wang, A., Li, G., Su, L., & Chen, S. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00905-7 · Cited by 22
Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR
Workman, P., & Clarke, P. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.020 · Cited by 22
Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to Cisplatin
Yang, F., Wang, L., Han, X., Liu, X., Ma, H., & Ding, Y. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.1.042 · Cited by 22
Fukuoka, M., Yoshioka, K., & Hohjoh, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201796 · Cited by 22
Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21
Bar, J., & Onn, A. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.001 · Cited by 21
Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy
Neirinckx, V., Hedman, H., & Niclou, S. P. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.007 · Cited by 21
Yi, Y. W., You, K. S., Han, S., Ha, I. J., Park, J., Lee, S., & Seong, Y. (2022) · Cancers · doi:10.3390/cancers14215215 · Cited by 21
Opo, F. A. D. M., Moulay, M., Zari, A., Alqaderi, A., Alkarim, S., Zari, T. A., Bhuiyan, M. A., Mahmoud, M. M., Aljoud, F., Suhail, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1027890 · Cited by 20
Pan, D., & Lin, X. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000001 · Cited by 23
Zhu, H., Gao, J., Wang, L., Qian, K., & Cai, L. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5695 · Cited by 20
Acquired Resistance in Lung Cancer
Tulpule, A., & Bivona, T. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033502 · Cited by 21
Self-citationGenomic aberrations guiding treatment of non-small cell lung cancer patients
Saber, A., van der Wekken, A. J., Hiltermann, T. J. N., Kok, K., van den Berg, A., & Groen, H. J. M. (2015) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2015.03.005 · Cited by 19
Protease addiction and synthetic lethality in cancer
Freije, J. M. P. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00025 · Cited by 20
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19
Zhong, J., Bai, H., Wang, Z., Duan, J., Zhuang, W., Wang, D., Wan, R., Xu, J., Fei, K., Ma, Z., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0976-4 · Cited by 19
Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment
Saxon, J. A., Sherrill, T. P., Polosukhin, V. V., Sai, J., Zaynagetdinov, R., McLoed, A. G., Gulleman, P. M., Barham, W. J., Cheng, D., Hunt, R. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1168549 · Cited by 18
Ihn, H. J., Kim, J. A., Bae, Y. C., Shin, H., Baek, M., & Park, E. K. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.3.223 · Cited by 18
Yao, J., Liang, X., Xu, S., Liu, Y., Shui, L., Li, S., Guo, H., Xiao, Z., Zhao, Y., & Zheng, M. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.11.035 · Cited by 17
Poor antibody validation is a challenge in biomedical research: a case study for detection of c-FLIP
Bucur, O., Pennarun, B., Stancu, A. L., Nadler, M. J. S., Muraru, M. S., Bertomeu, T., & Khosravi‐Far, R. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0880-0 · Cited by 17
Rho, J. K., Lee, I. Y., Choi, Y. J., Choi, C., Hur, J.-Y., Koh, J. S., Lee, J., Suh, B., Song, H., Salgaonkar, P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2432 · Cited by 17
Self-citationBhateja, P., Dowlati, A., & Sharma, N. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0515-3 · Cited by 17
Ni, J., Zhou, L., Ding, L. J., Zhang, X., Zhao, X., Li, H., Cao, H., Liu, S., Wang, Z., Ma, R., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1440 · Cited by 17
Plasmatic membrane toll-like receptor expressions in human astrocytomas
Moretti, I. F., Franco, D. G., Galatro, T. F. D. A., Oba‐Shinjo, S. M., & Marie, S. K. N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199211 · Cited by 18
c-FLIP and CD95 signaling are essential for survival of renal cell carcinoma
Luebke, T., Schwarz, L., Beer, Y. Y., Schumann, S., Misterek, M. B., Sander, F. E., Plaza‐Sirvent, C., & Schmitz, I. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1609-y · Cited by 17
Wang, R., Peng, S., Zhang, X., Wu, Z., Duan, H., Yuan, Y., & Wang, W. (2018) · International Journal of Cancer · doi:10.1002/ijc.31907 · Cited by 17
Cheng, J., & Cashman, J. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-65804-5 · Cited by 17
Shie, M., Fang, H., Kan, K., Ho, C., Tu, C., Lee, P., Hsueh, P., Chen, C., Lee, A. K.-X., Tien, N., et al. (2023) · Advanced Science · doi:10.1002/advs.202206603 · Cited by 16
Using functional genomics to overcome therapeutic resistance in hematological malignancies
Calderon, F. A., Gregory, M. A., & DeGregori, J. V. (2012) · Immunologic Research · doi:10.1007/s12026-012-8353-z · Cited by 18
Vyse, S., Howitt, A., & Huang, P. H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.018 · Cited by 16
Mutation Profile of ResectedEGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing
Zhao, Z.-R., Lin, Y., Ng, C. S. H., Zhang, R., Wu, X., Ou, Q., Chen, W., Zhou, W., Lin, Y., Su, X., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0567 · Cited by 16
JNK initiates Beclin-1 dependent autophagic cell death against Akt activation
Zeng, C., Zhang, Z., Luo, W., Wang, L., Zhou, H., & Nie, C. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113105 · Cited by 17
Wei, N., Song, Y., Zhang, F., Sun, Z., & Zhang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01424 · Cited by 15
Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer
Farnsworth, D., Chen, Y. T., de Rappard-Yuswack, G., & Lockwood, W. W. (2021) · Cells · doi:10.3390/cells10123553 · Cited by 16
Liu, S., Cao, H., Chen, D., Yu, S., Sha, H., Wu, J., Ma, R., Wang, Z., Jing, C., Zhang, J., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8182 · Cited by 15
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance
Roberts, S. K., Galgadas, I., Clarke, D. T., Zanetti-Domingues, L. C., Gervasio, F. L., & Martin-Fernandez, M. L. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104407 · Cited by 14
Reddy, T. P., Choi, D. S., Anselme, A. C., Qian, W. P., Chen, W., Lantto, J., Horak, I. D., Kragh, M., Chang, J. C., & Rosato, R. R. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01280-z · Cited by 14
Sadler, K. V., Bowes, J., Rowlands, C. F., Perez‐Becerril, C., van der Meer, C. M., King, A. T., Rutherford, S. A., Pathmanaban, O. N., Hammerbeck-Ward, C. L., Lloyd, S., et al. (2022) · Brain · doi:10.1093/brain/awac478 · Cited by 14
The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis
Fouqué, A., & Legembre, P. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_9 · Cited by 15
Hong, S. H., Kang, N., Kim, O., Hong, S. A., Park, J., Kim, J., Lee, M. A., & Kang, J. (2022) · Cancers · doi:10.3390/cancers15010124 · Cited by 14
Li, H., Liu, J., Sun, Y., Wang, W., Weng, S., Xiao, S., Huang, H., & Zhang, W. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2893 · Cited by 13
Pharmacological management of relapsed/refractory NSCLC with chemical drugs
Karachaliou, N., Sosa, A. E., Barrón, F., Cao, M. G., Santarpía, M., & Rosell, R. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285284 · Cited by 13
Self-citationSoluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?
Kurma, K., Boizard-Moracchini, A., Galli, G., Jean, M., Vacher, P., Blanco, P., & Legembre, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188596 · Cited by 14
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 14
Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs
Bousoik, E., Nabiee, R., Amirrad, F., Nichols, A., Witt, R., Mahdipoor, P., & Aliabadi, H. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01070 · Cited by 13
Jeong, I., Song, J., Bae, S. Y., & Lee, S. K. (2019) · Journal of Cancer Prevention · doi:10.15430/jcp.2019.24.4.217 · Cited by 13
Costanzo, R., Montanino, A., Maïo, M. D., Piccirillo, M. C., Sandomenico, C., Giordano, P., Daniele, G., Franco, R., Perrone, F., Rocco, G., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.845092 · Cited by 12
Pan, Y., Lin, C., Lu, C., Li, L., Wang, Y., Chen, H., & He, Y. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12970 · Cited by 12
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
Karachaliou, N., Codony‐Servat, J., Bracht, J. W. P., Ito, M., Filipska, M., Pedraz‐Valdunciel, C., CHAIB-OUKADOUR, I., Bertrán-Alamillo, J., Cardona, A. F., Molina‐Vila, M. Á., et al. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656068 · Cited by 13
Self-citationOrozco‐Morales, M., Hernández‐Pedro, N., Barrios‐Bernal, P., Arrieta, O. G., Ruiz-Godoy, L. M., Aschner, M., Santamarı́a, A., & Colín-González, A. L. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001015 · Cited by 12
Hsiao, S.-H., Liu, H. E., Lee, H.-L., Lin, C.-L., Chen, W., Wu, Z.-H., Lin, S., Chiang, L.-L., & Chung, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083266 · Cited by 12
Value-added anticancer reactivity of sub-5 nm Ag-drug nanoparticles derived from organosilver(I) MOF
Song, C., Zhang, J., Qiu, Y., Jin, H.-P., Zhang, H., Liu, S., Liu, H., Qiu, H., & Gao, G. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9376-7 · Cited by 12
The Crosstalk of Apoptotic and Non-Apoptotic Signaling in CD95 System
Seyrek, K., Espe, J., Reiss, E., & Lavrik, I. N. (2024) · Cells · doi:10.3390/cells13211814 · Cited by 13
Hong, X., Hsieh, M., Tseng, T.-Y., Lin, H., Chang, H., Yau, S.-T., Cheng, W., Ke, B., Liao, H.-H., Wu, C., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104814 · Cited by 11
Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer
Kondratyev, M. K., Pesic, A., Ketela, T., Stickle, N. H., Beswick, C., Shalev, Z., Marastoni, S., Samadian, S., Dvorkin‐Gheva, A., Sayad, A., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04828-9 · Cited by 12
Jinushi, M. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9501-9 · Cited by 11
Adil, M. M., Levine, R. M., & Kokkoli, E. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400535v · Cited by 11
Fruscella, M., Ponzetto, A., Crema, A., & Carloni, G. (2016) · Journal of Nanotechnology · doi:10.1155/2016/3020361 · Cited by 11
Kim, T. Y., Ji, E. S., Lee, J. Y., Kim, J. Y., Yoo, J. S., Szász, A. M., Döme, B., Marko‐Varga, G., & Kwon, H. J. (2020) · Cancers · doi:10.3390/cancers12092613 · Cited by 11
Metadata
- Authors
- Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., Hannon, G., & Sawyers, C. L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Cold Spring Harbor Laboratory (US)
- Institut Català d'Oncologia (ES)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Sawyers, Charles L.
- ORCID
- Venue
- Nature
- Published
- 2011-03
- Volume
- 471
- Issue
- 7339
- Pages
- 523-526
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3541675
- OpenAlex
- W2087955215
- Cited by
- 396
- References
- 24
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 14 · 2022: 20 · 2021: 19 · 2020: 17 · 2019: 33 · 2018: 46 · 2017: 38 · 2016: 25 · 2015: 27 · 2014: 37 · 2013: 37 · 2012: 39
- FWCI
- 37.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Memorial Sloan-Kettering Cancer Center
- National Cancer Institute (P01CA013106)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- NF-κB signaling, erlotinib, EGFR tyrosine kinase inhibitors, drug resistance, IκB, c-FLIP, IκB kinase, RNAi screen, lung adenocarcinoma, apoptosis, combination therapy, treatment response biomarkers, non-smoker lung cancer
- MeSH terms
- Erlotinib Hydrochloride, Dose-Response Relationship, Drug, Humans, Lung Neoplasms, Models, Biological, Mutation, Quinazolines, Signal Transduction, Down-Regulation, NF-kappa B, Genes, erbB-1, Drug Resistance, Neoplasm, fas Receptor, I-kappa B Proteins, RNA Interference, Cell Line, Tumor, Mutant Proteins, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
